title: Chronic hepatitis B and C co-infection increased all-cause mortality in HAART-naive HIV patients in Northern Thailand.
abstract: A total of 755 highly active antiretroviral therapy (HAART)-naive HIV-infected patients were enrolled at a government hospital in Thailand from 1 June 2000 to 15 October 2002. Census dateo f survival was on 31 October 2004 or the date of HAART initiation. Of 700 (92.6%) patients with complete data, the prevalence of hepatitis B virus (HBV) surface antigen and anti-hepatitis C virus (HCV) antibody positivity was 11.9% and 3.3%, respectively. Eight (9.6%) HBV co-infected patients did not have anti-HBV core antibody (anti-HBcAb). During 1166.7 person-years of observation (pyo), 258 (36.9%) patients died [22.1/100 pyo, 95% confidence interval (CI) 16.7–27.8]. HBV and probably HCV co-infection was associated with a higher mortality with adjusted hazard ratios (aHRs) of 1.81 (95% CI 1.30–2.53) and 1.90 (95% CI0.98–3.69), respectively. Interestingly, HBV co-infection without anti-HBc Ab was strongly associated with death (aHR 6.34, 95% CI 3.99–10.3). The influence of hepatitis co-infection on the natural history of HAART-naive HIV patients requires greater attention.
authors.affiliation: Department of Clinical Medicine, Institute of Tropical Medicine NEKKEN, Nagasaki University, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Tsuchiya
authors.forename: P
authors.initials: P
authors.lastname: Pathipvanich
authors.forename: A
authors.initials: A
authors.lastname: Rojanawiwat
authors.forename: N
authors.initials: N
authors.lastname: Wichukchinda
authors.forename: I
authors.initials: I
authors.lastname: Koga
authors.forename: M
authors.initials: M
authors.lastname: Koga
authors.forename: W
authors.initials: W
authors.lastname: Auwanit
authors.forename: P E
authors.initials: PE
authors.lastname: Kilgore
authors.forename: K
authors.initials: K
authors.lastname: Ariyoshi
authors.forename: P
authors.initials: P
authors.lastname: Sawanpanyalert
mesh_terms: D000328:Adult; D060085:Coinfection / Q000401:mortality*; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000401:mortality*; D006514:Hepatitis B Surface Antigens / Q000097:blood; D019694:Hepatitis B, Chronic / Q000150:complications* / Q000453:epidemiology / Q000401:mortality*; D018937:Hepatitis C Antibodies / Q000097:blood; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000453:epidemiology / Q000401:mortality*; D006801:Humans; D008297:Male; D016036:Seroepidemiologic Studies; D016019:Survival Analysis; D013785:Thailand / Q000453:epidemiology
chemical_list: D006514:Hepatitis B Surface Antigens; D018937:Hepatitis C Antibodies